See more : Anixa Biosciences, Inc. (ANIX) Income Statement Analysis – Financial Results
Complete financial analysis of Nektar Therapeutics (NKTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nektar Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hangzhou Arcvideo Technology Co., Ltd. (688039.SS) Income Statement Analysis – Financial Results
- Eclatorq Technology Co., Ltd. (6855.TWO) Income Statement Analysis – Financial Results
- 4GLOBAL plc (4GBL.L) Income Statement Analysis – Financial Results
- HOV Services Limited (HOVS.NS) Income Statement Analysis – Financial Results
- Glori Energy Inc. (GLRI) Income Statement Analysis – Financial Results
Nektar Therapeutics (NKTR)
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.12M | 92.06M | 101.91M | 152.92M | 114.62M | 1.19B | 307.71M | 165.44M | 230.78M | 200.71M | 148.92M | 81.19M | 71.48M | 159.04M | 71.93M | 90.19M | 273.03M | 217.72M | 126.28M | 114.27M | 106.26M | 94.85M | 77.47M | 51.63M | 41.36M | 21.80M | 16.25M | 6.90M | 3.40M | 1.70M |
| Cost of Revenue | 36.64M | 21.64M | 24.90M | 19.48M | 21.37M | 24.41M | 30.55M | 30.22M | 34.10M | 28.53M | 38.51M | 30.43M | 21.89M | 25.67M | 30.95M | 35.04M | 147.52M | 118.09M | 36.00M | 19.80M | 14.68M | 7.02M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.10M | -500.00K |
| Gross Profit | 53.48M | 70.42M | 77.01M | 133.44M | 93.24M | 1.17B | 277.16M | 135.22M | 196.68M | 172.17M | 110.41M | 50.76M | 49.59M | 133.37M | 40.98M | 55.15M | 125.51M | 99.63M | 90.28M | 94.47M | 91.58M | 87.83M | 73.30M | 51.63M | 41.36M | 21.80M | 16.25M | 8.10M | 4.50M | 2.20M |
| Gross Profit Ratio | 59.34% | 76.50% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% | 61.15% | 45.97% | 45.76% | 71.49% | 82.67% | 86.19% | 92.60% | 94.62% | 100.00% | 100.00% | 100.00% | 100.00% | 117.39% | 132.35% | 129.41% |
| Research & Development | 114.16M | 218.32M | 400.27M | 408.68M | 434.57M | 399.54M | 268.46M | 203.80M | 182.79M | 147.73M | 190.01M | 148.68M | 126.77M | 108.07M | 95.11M | 154.42M | 153.58M | 149.38M | 151.66M | 133.52M | 131.53M | 157.38M | 139.65M | 101.54M | 64.08M | 35.40M | 23.65M | 14.40M | 9.00M | 0.00 |
| General & Administrative | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 3.20M | 7.40M |
| Other Expenses | 0.00 | -116.00K | -24.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 392.00K | 983.00K | 0.00 | 0.00 | 0.00 | -68.11M | -48.25M | 31.16M | 69.55M | 3.92M | 4.22M | 4.51M | 25.49M | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 4.30M | 7.90M |
| Operating Expenses | 190.90M | 310.66M | 523.11M | 513.36M | 533.28M | 480.98M | 320.83M | 248.08M | 226.05M | 188.66M | 230.54M | 190.29M | 173.53M | 149.05M | 136.12M | 137.80M | 161.66M | 258.86M | 265.06M | 168.41M | 157.76M | 187.91M | 184.00M | 115.48M | 71.95M | 43.79M | 29.97M | 19.60M | 13.30M | 7.90M |
| Cost & Expenses | 227.55M | 332.29M | 548.01M | 532.84M | 554.65M | 505.39M | 351.37M | 278.29M | 260.16M | 217.19M | 269.05M | 220.72M | 195.42M | 174.72M | 167.06M | 172.84M | 309.18M | 376.95M | 301.05M | 188.21M | 172.44M | 194.93M | 188.17M | 115.48M | 71.95M | 43.79M | 29.97M | 18.40M | 12.20M | 7.40M |
| Interest Income | 19.01M | 6.67M | 2.57M | 18.28M | 46.34M | 37.57M | 4.52M | 2.39M | 1.68M | 814.00K | 732.00K | 2.32M | 2.24M | 1.55M | 3.69M | 12.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.33M | 28.91M | 47.31M | 37.12M | 46.35M | 42.78M | 40.95M | 42.18M | 38.90M | 38.76M | 40.76M | 33.55M | 10.22M | 11.17M | 12.18M | 15.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.82M | 12.20M | 13.00M | 12.50M | 11.00M | 8.80M | 12.60M | 13.20M | 12.86M | 12.93M | 14.28M | 14.51M | 14.95M | 16.55M | 14.88M | 22.49M | 28.15M | 32.64M | 26.23M | 19.19M | 18.42M | 18.97M | 40.39M | 10.12M | 7.25M | 3.60M | 2.44M | 1.20M | 1.10M | 500.00K |
| EBITDA | -243.11M | -323.87M | -462.97M | -394.33M | -382.70M | 734.30M | -42.52M | -97.27M | -29.37M | -2.74M | -106.01M | -124.10M | -107.79M | -9.33M | -75.72M | 2.54M | -7.12M | -125.72M | -147.07M | -54.76M | -47.77M | -81.11M | -70.32M | -53.72M | -23.34M | -18.39M | -11.29M | -10.30M | -7.70M | -5.20M |
| EBITDA Ratio | -269.75% | -239.57% | -445.31% | -227.22% | -332.01% | 61.71% | -7.93% | -57.49% | -6.43% | -1.37% | -70.33% | -149.92% | -149.33% | 1.52% | -106.44% | -197.91% | -21.36% | -46.66% | -58.44% | -40.07% | -75.27% | -84.47% | 103.45% | -22.74% | -32.52% | -84.39% | -69.46% | -172.46% | -264.71% | -341.18% |
| Operating Income | -137.43M | -240.24M | -446.10M | -379.92M | -440.04M | 687.93M | -59.64M | -112.86M | -29.37M | -16.49M | -120.13M | -141.20M | -123.94M | -28.26M | -95.13M | -82.65M | -36.15M | -159.23M | -182.63M | -73.94M | -66.19M | -100.08M | -256.96M | -66.14M | -40.48M | -21.99M | -13.72M | -11.50M | -8.80M | -5.70M |
| Operating Income Ratio | -152.49% | -260.97% | -437.76% | -248.45% | -383.92% | 57.65% | -19.38% | -68.22% | -12.73% | -8.21% | -80.67% | -173.91% | -173.39% | -17.77% | -132.25% | -91.65% | -13.24% | -73.14% | -144.63% | -64.71% | -62.29% | -105.52% | -331.70% | -128.10% | -97.89% | -100.89% | -84.46% | -166.67% | -258.82% | -335.29% |
| Total Other Income/Expenses | -138.83M | -124.75M | -77.18M | -64.03M | -19.00K | -5.21M | -36.43M | -39.79M | -51.30M | -37.94M | -39.64M | -30.25M | -9.02M | -8.80M | -7.64M | 47.51M | 4.70M | 5.30M | -2.62M | -28.11M | 19.67M | -7.39M | 6.96M | -31.26M | -9.89M | 0.00 | 0.00 | 1.60M | 1.30M | 600.00K |
| Income Before Tax | -276.26M | -364.98M | -523.28M | -443.95M | -440.05M | 682.73M | -96.08M | -152.65M | -80.67M | -54.43M | -159.77M | -171.45M | -132.96M | -37.06M | -102.77M | 35.14M | -31.45M | -153.93M | -185.25M | -102.05M | -46.51M | -107.47M | -250.01M | -97.40M | -50.37M | 0.00 | 0.00 | -9.90M | -7.50M | -5.10M |
| Income Before Tax Ratio | -306.54% | -396.48% | -513.49% | -290.32% | -383.93% | 57.21% | -31.22% | -92.27% | -34.96% | -27.12% | -107.28% | -211.17% | -186.01% | -23.30% | -142.88% | 38.97% | -11.52% | -70.70% | -146.70% | -89.31% | -43.77% | -113.31% | -322.72% | -188.66% | -121.80% | 0.00% | 0.00% | -143.48% | -220.59% | -300.00% |
| Income Tax Expense | -200.00K | 3.22M | 557.00K | 493.00K | 613.00K | 1.41M | 616.00K | 876.00K | 506.00K | -512.00K | 2.25M | 406.00K | 1.02M | 881.00K | -253.00K | -806.00K | 1.31M | 828.00K | -137.00K | -163.00K | 169.00K | 7.39M | 139.31M | 33.56M | 7.85M | -3.63M | -3.74M | -1.50M | -1.10M | -400.00K |
| Net Income | -276.06M | -368.20M | -523.84M | -444.44M | -440.67M | 681.31M | -96.69M | -153.52M | -81.18M | -53.92M | -162.01M | -171.86M | -133.98M | -37.94M | -102.52M | -34.34M | -32.76M | -154.76M | -185.11M | -101.89M | -46.68M | -107.47M | -250.01M | -97.40M | -38.45M | -18.36M | -9.98M | -10.00M | -7.70M | -5.30M |
| Net Income Ratio | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | 57.09% | -31.42% | -92.80% | -35.17% | -26.86% | -108.79% | -211.67% | -187.43% | -23.85% | -142.52% | -38.07% | -12.00% | -71.08% | -146.59% | -89.16% | -43.93% | -113.31% | -322.72% | -188.66% | -92.96% | -84.22% | -61.44% | -144.93% | -226.47% | -311.76% |
| EPS | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| EPS Diluted | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.57M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
| Weighted Avg Shares Out (Dil) | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.60M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell...
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved complete remission, all without detectable MRD – SAN FRANCISCO , Oct. 17,...
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis - SAN FRANCISCO , Sept. 25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...
Nektar Management to Present at Upcoming Investor Conferences
SAN FRANCISCO , Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: H.C.
What Makes Nektar (NKTR) a New Buy Stock
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.27 per share a year ago.
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
SAN FRANCISCO , Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to...
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive...
Source: https://incomestatements.info
Category: Stock Reports